Osivax Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
2ndary - Private
- Investors
-
19
Osivax General Information
Description
Developer of universal vaccines designed to prevent globally impactful infectious diseases, starting with influenza. The company leverages its technology and acts as a universal vaccine against all existing and emerging coronavirus infections to prevent globally impactful contagious diseases, enabling medical practitioners to treat patients with cancer, influenza, malaria, and other infectious diseases effectively.
Contact Information
Website
www.osivax.comCorporate Office
- Swely Building C Slam
- 70 Rue Saint Jean Dieu
- 69007 Lyon
- France
Corporate Office
- Swely Building C Slam
- 70 Rue Saint Jean Dieu
- 69007 Lyon
- France
Osivax Timeline
Osivax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Secondary Transaction - Private | 01-Mar-2026 | Completed | Clinical Trials - Phase 2 | |||
| 14. Grant | 26-Aug-2025 | Completed | Clinical Trials - Phase 2 | |||
| 13. Later Stage VC (Series B1) | 04-Mar-2025 | Completed | Clinical Trials - Phase 2 | |||
| 12. Grant | 05-Dec-2023 | Completed | Clinical Trials - Phase 1 | |||
| 11. Later Stage VC | 11-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
| 10. Grant | 28-Mar-2023 | Completed | Clinical Trials - Phase 1 | |||
| 9. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 | ||||
| 8. Grant | 23-Jun-2022 | Completed | Clinical Trials - Phase 1 | |||
| 7. Early Stage VC (Series B) | 29-Jul-2021 | $17.9M | $35M | Completed | Clinical Trials - Phase 1 | |
| 6. Grant | 18-Mar-2020 | $2.72M | $17.1M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Osivax Comparisons
Industry
Financing
Details
Osivax Competitors (21)
One of Osivax’s 21 competitors is Gylden Pharma, a Venture Capital-Backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gylden Pharma | Venture Capital-Backed | Abingdon, United Kingdom | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| RootPath | Venture Capital-Backed | Framingham, MA | ||||
| Seekyo | Venture Capital-Backed | Poitiers, France | ||||
| Step Pharma | Venture Capital-Backed | Saint-Genis-Pouilly, France |
Osivax Patents
Osivax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023237601-A1 | Mrna vaccine compositions and their use | Pending | 22-Mar-2022 | ||
| AU-2023237601-A9 | Mrna vaccine compositions and their use | Pending | 22-Mar-2022 | ||
| EP-4496578-A1 | Mrna vaccine compositions and their use | Pending | 22-Mar-2022 | ||
| US-20240139300-A1 | Mrna vaccine compositions and their use | Pending | 22-Mar-2022 | ||
| WO-2023180394-A1 | Mrna vaccine compositions and their use | Inactive | 22-Mar-2022 | A61K31/7105 |
Osivax Signals
Osivax Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | |||
| Issarts Capital | PE/Buyout | Minority | ||
| Meiji Seika Pharma | Corporation | Minority | ||
| Le territoire en Wallonie | Corporation | Minority | ||
| Gates Foundation | Not-For-Profit Venture Capital |
Osivax FAQs
-
When was Osivax founded?
Osivax was founded in 2017.
-
Where is Osivax headquartered?
Osivax is headquartered in Lyon, France.
-
What is the size of Osivax?
Osivax has 50 total employees.
-
What industry is Osivax in?
Osivax’s primary industry is Drug Discovery.
-
Is Osivax a private or public company?
Osivax is a Private company.
-
What is Osivax’s current revenue?
The current revenue for Osivax is .
-
How much funding has Osivax raised over time?
Osivax has raised $45.4M.
-
Who are Osivax’s investors?
U.S. Department of Health and Human Services, Issarts Capital, Meiji Seika Pharma, Le territoire en Wallonie, and Gates Foundation are 5 of 19 investors who have invested in Osivax.
-
Who are Osivax’s competitors?
Gylden Pharma, Inovio Pharmaceuticals, RootPath, Seekyo, and Step Pharma are some of the 21 competitors of Osivax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process